INTERVIEW: Grey areas and holes in CMS’ CED draft leave US industry seeking document changes
This article was originally published in Clinica
Executive Summary
The application of CED, coverage with evidence development, for medical devices reaching – or already on – the US market, is one of the main priorities for US industry right now. So says Chandra Branham, the VP of payment & healthcare delivery policy within US industry association AdvaMed.